Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
MedPage Today on MSN6d
Myasthenia Gravis ExacerbationsGeneralized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...
Generalized myasthenia gravis (gMG) happens when the immune system ... protein to prevent neuromuscular damage and help relieve symptoms. First approved in 2007, the drug is already used for ...
Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...
Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
On World Rare Diseases Day, read on to learn more about Myasthenia Gravis, a complex autoimmune disorder that requires ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Decreased AChR-Ab titers correlated with improved myasthenia gravis symptoms, especially in ADL scores, within the first 3 months of treatment. The study found no baseline correlation between AChR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback